基于RPPA的蛋白质组学识别慢性淋巴细胞白血病中具有临床意义的不同表观遗传特征
该研究利用反相蛋白阵列技术对871例慢性淋巴细胞白血病及相关疾病样本进行分析,识别出四种表观遗传上不同的蛋白质组特征。这些特征与年龄、细胞遗传学异常、IGHV突变负荷、ZAP-70状态、Binet和Rai分期以及至治疗时间和总生存期相关。蛋白质特征归属被确定为总生存期的预测标志物,且独立于其他临床特征。
要点
- RPPA蛋白质组学可识别CLL中四种表观遗传上不同的特征。
- 这些特征与临床特征及至治疗时间、总生存期相关。
- EZH2、HDAC6及H3K27me3缺失与不良生存独立相关。
核心结论
- 基于蛋白质组学的表观遗传生物标志物可用于更好地对CLL患者进行分类并提供治疗指导。
研究设计与样本
- 研究采用反相蛋白阵列技术,对871例CLL及相关疾病来源样本进行分析。
主要发现
- 识别出四种表观遗传上不同的蛋白质组特征,与年龄、细胞遗传学异常[12三体、del(13q)和del(17p)]、IGHV突变负荷、ZAP-70状态、Binet和Rai分期相关。
- 蛋白质特征归属与至治疗时间和总生存期相关,且为总生存期的预测标志物,独立于其他临床特征。
- 在分析的表观遗传蛋白中,EZH2、HDAC6和H3K27me3水平缺失与不良生存最为独立相关。
临床怎么用
- 蛋白质组学表观遗传标志物可用于CLL患者的风险分层和治疗指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The chronic lymphocytic leukemia (CLL) armamentarium has evolved significantly, with novel therapies that inhibit Bruton Tyrosine Kinase, PI3K delta and/or the BCL2 protein improving outcomes. Still, the clinical course of CLL patients is highly variable and most previously recognized prognostic features lack the capacity to predict response to modern treatments indicating the need for new prognostic markers. In this study, we identified four epigenetically distinct proteomic signatures of a large cohort of CLL and related diseases derived samples (n = 871) using reverse phase protein array technology. These signatures are associated with clinical features including age, cytogenetic abnormalities [trisomy 12, del(13q) and del(17p)], immunoglobulin heavy-chain locus (IGHV) mutational load, ZAP-70 status, Binet and Rai staging as well as with the outcome measures of time to treatment and overall survival. Protein signature membership was identified as predictive marker for overall survival regardless of other clinical features. Among the analyzed epigenetic proteins, EZH2, HDAC6, and loss of H3K27me3 levels were the most independently associated with poor survival. These findings demonstrate that proteomic based epigenetic biomarkers can be used to better classify CLL patients and provide therapeutic guidance.
引用
- van Dijk AD, Griffen TL, Qiu YH, et al. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2021. PMID: 34625713. doi:10.1038/s41375-021-01438-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。